#United States #New York #Securities Fraud #PACS Group #Rosen Law

Attention PACS Group Inc. Shareholders

The Rosen Law Firm, a prominent player in the field of investor rights, has reached out to those who purchased common stock of PACS Group Inc. (NYSE: PACS). The firm is reminding these investors of a critical opportunity to involve themselves in a securities fraud class action lawsuit against the company, following allegations of misleading practices surrounding its initial public offering (IPO) and subsequent secondary offering.

Background Information

PACS Group Inc. launched its IPO on April 11, 2024, allowing investors a chance to buy into the company based on what they believed to be sound corporate practices and financial health. However, recent developments indicate that the company was allegedly engaged in fraudulent activities, including the submission of false Medicare claims that significantly inflated its financial results from 2020 through 2023. Given the seriousness of these allegations, affected investors are urged to consider joining the class action which aims to hold the company accountable for its actions.

Class Action Details

Individuals who purchased PACS common stock either during the IPO or in the period from April 11, 2024, to November 5, 2024, may have claims for compensation. Investors are reminded that the deadline to act as lead plaintiff in this class action is set for January 13, 2025. As a lead plaintiff, one would not only represent their interests but also those of other investors in guiding the litigation.

The Rosen Law Firm emphasizes that taking part in this class action does not require any out-of-pocket costs thanks to their contingency fee arrangement. Investors wishing to learn more can visit this link or call Phillip Kim, Esq. at 866-767-3653.

Why Choose Rosen Law Firm?

Rosen Law Firm stands out for its track record of successfully managing securities class actions. They have secured major settlements and are noted for their experience—having been recognized as a leader in the field. The firm was ranked as having the most successful securities class action settlements in 2017 and has continually maintained a strong reputation since then. Investors should be cautious of firms that act merely as intermediaries without the necessary litigation experience.

The Allegations Against PACS Group

The core of the class action lawsuit centers on allegations that the Registration Statement for the IPO contained misleading information and omitted crucial facts. Specifically, investors are citing issues such as:

• - Allegations of the company engaging in a scheme to generate false documentation related to Medicare claims.
• - The billing of unnecessary therapy services, further misrepresenting the company’s financial integrity.
• - Misleading statements about the company’s operations and overall growth potential, which led to inflated stock prices and investor losses when the truth was revealed.

As these details came to light, they've potentially placed PACS Group in a precarious legal standing and resulted in significant financial damages for investors.

Next Steps for Investors

If you're a shareholder from the specified class period, you're advised to take immediate action if you wish to participate in this class action lawsuit. You can either join as an absent class member, needing no direct action or representation, or you could step up as a lead plaintiff to guide the case against PACS Group. However, until the class is certified by the court, individual investors should consult their chosen legal counsel.

For ongoing updates, Rosen Law Firm encourages you to follow them on social media platforms including LinkedIn, Twitter, and Facebook for more news and developments related to this case.

In summary, this could be an important moment for investors of PACS Group Inc. as they navigate their rights and potential for compensation against practices they may not have previously known about. Don’t wait for the deadline; take action now.